Back

Clinical and haemodynamic effects of percutaneous edge-to-edge mitral valve repair in atrial versus ventricular functional mitral regurgitation

27 August 2021 (20:51 - 21:00)
Organised by:
Congress Presentation Part of: A deep dive into mitral regurgitation Intervention ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Marc Claeys

University of Antwerp, Antwerp (Belgium)

4 More presentations in this session

Presentation thumbnail
Circulating transforming growth factor-beta1 and progression of the mitral valve prolapse: fifteen-year follow-up
Professor E. Malev (Saint Petersburg, RU)
Abstract Slides Video
Presentation thumbnail
Trends in incidence and mortality from non-rheumatic degenerative mitral valve disease across europe, over the past three decades.
Doctor B. Al-khayatt (London, GB)
Abstract Slides Video
Presentation thumbnail
The MIDA Quantitative mortality risk score: prognostic model in floppy mitral valves
Doctor B. Essayagh (Cannes, FR)
Abstract Slides Video
Presentation thumbnail
Myocardial efficiency in severe asymptomatic primary mitral regurgitation: relation to quantitative measures of regurgitation
Professor J. Sorensen (Uppsala, SE)
Abstract Slides Video

Access the full session

Session thumbnail
A deep dive into mitral regurgitation

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 20:51 CET
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes after edge-to-edge percutaneous repair in atrial versus ventricular functional mitral regurgitation
thumbnail
Congress Presentation
The prognostic role of left atrial mechanics but not left ventricular function in functional mitral regurgitation
thumbnail
Congress Presentation
Transcatheter treatment of severe mitral regurgitation in high surgical risk patients: analysis of clinical and echocardiographic data from a referral center

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources